Top

Published in:

01-09-2016 | Original Article

Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus

Authors: Jinxian Huang, Guoxiang Song, Zhihua Yin, Weizhen He, Lijun Zhang, Weihong Kong, Zhizhong Ye

Published in: Clinical Rheumatology | Issue 9/2016

Abstract

This was an exploratory analysis comparing the safety and efficacy of immunoadsorption (IAS) combination therapy in severe systemic lupus erythematosus (SLE) receiving corticosteroid pulse and immunosuppressant treatment. Patients enrolled all had predominant organ involvement including proteinuria, thrombocytopenia, pericardial effusion, and cerebral involvement requiring corticosteroid pulse treatment. Fifty-two patients in study group received IAS plus corticosteroid and cyclophosphamide treatment. Fifty-two patients in non-IAS group received corticosteroid and cyclophosphamide treatment. Outcome measurement included C3, dsDNA, AnuA, and SLE disease activity index (SLEDAI) 2k score and in particular cases, proteinuria quantification and platelet count. Disease activity dropped significantly in both groups. Improvement of disease activity markers was more significant in study group than that in non-IAS group. The lower dosage of steroid in study group suggested the steroid-sparing effect of IAS. No severe adverse effect occurred during IAS. Our study suggested IAS as an additional therapy to steroid pulse and immunosuppressant in treating severe SLE.

Available only for authorised users

Wener MH (2007) Immune complexes in systemic lupus erythematosus. In: Tsokos GC, Gordon C, Smolen JS (eds) Systemic lupus erythematosus, 1st edn. Mosby, Philadelphia, pp 214–224CrossRef

Hershko AY, Naparstek Y (2005) Removal of pathogenic autoantibodies by immunoadsorption. Ann N Y Acad Sci 1051:635–646, PubMed: 16127004CrossRefPubMed

Stummvoll GH (2011) Immunoadsorption (IAS) for systemic lupus erythematosus. Lupus 20(2):115–119, PubMed: 21303827CrossRefPubMed

Loo CY, Mohamed Said MS, Mohd R, Abdul Gafor AH, Saidin R, Halim NA et al (2010) Immunoadsorption and plasmapheresis are equally efficacious as adjunctive therapies for severe lupus nephritis. Transfus Apher Sci 43(3):335–340CrossRefPubMed

Stummvoll GH, Schmaldienst S, Smolen JS, Derfler K, Biesenbach P (2012) Lupus nephritis: prolonged immunoadsorption (IAS) reduces proteinuria and stabilizes global disease activity. Nephrol Dial Transplant 27(2):618–626, PubMed: 21617196CrossRefPubMed

Stummvoll GH, Aringer M, Smolen JS, Schmaldienst S, Jiménez-Boj E, Hörl WH et al (2005) IgG immunoadsorption reduces systemic lupus erythematosus activity and proteinuria: a long term observational study. Ann Rheum Dis 64(7):1015–1021, PubMed: 15640267CrossRefPubMedPubMedCentral

Biesenbach P, Schmaldienst S, Smolen JS, Hörl WH, Derfler K, Stummvoll GH (2009) Immunoadsorption in SLE: three different high affinity columns are adequately effective in removing autoantibodies and controlling disease activity. Atheroscler Suppl 29; 10(5):114–121CrossRef

Amital H, Heilweil-Harel M, Ulmansky R, Harlev M, Toubi E, Hershko A et al (2007) Antibodies against the VRT101 laminin epitope correlate with human SLE disease activity and can be removed by extracorporeal immunoadsorption. Rheumatology 46:1433–1437, PubMed: 17686790CrossRefPubMed

Pfueller B, Wolbart K, Bruns A, Burmester GR, Hiepe F (2001) Successful treatment of patients with systemic lupus erythematosus by immunoadsorption with a C1q column: a pilot study. Arthritis Rheum 44(8):1962–1963, PubMed: 11508450CrossRefPubMed

10.

Berner B, Scheel AK, Schettler V, Hummel KM, Reuss-Borst MA, Müller GA et al (2001) Rapid improvement of SLE-specific cutaneous lesions by C1q immunoadsorption. Ann Rheum Dis 60(9):898–899, PubMed: 11534506PubMedPubMedCentral

11.

Funauchi M, Ikoma S, Enomoto H, Ohno M, Kinoshita K, Horiuchi A et al (1996) High-affinity anti-DNA antibody parallels clinical course of immunoadsorption therapy. Intern Med 35(5):367–372, PubMed: 8797048CrossRefPubMed

12.

Kinoshita M, Aotsuka S, Funahashi T, Tani N, Yokohari R (1989) Selective removal of anti-double-stranded DNA antibodies by immunoadsorption with dextran sulphate in a patient with systemic lupus erythematosus. Ann Rheum Dis 48(10):856–860, PubMed: 2479345CrossRefPubMedPubMedCentral

13.

Sugimoto K, Yamaji K, Yang KS, Kanai Y, Tsuda H, Hashimoto H (2006) Immunoadsorption plasmapheresis using a phenylalanine column as an effective treatment for lupus nephritis. Ther Apher Dial 10(2):187–192, PubMed: 16684222CrossRefPubMed

14.

Gaubitz M, Seidel M, Kummer S, Schotte H, Perniok A, Domschke W et al (1998) Prospective randomized trial of two different immunoadsorbers in severe systemic lupus erythematosus. J Autoimmun 11:495–501, PubMed: 9802935CrossRefPubMed

15.

Schneider M, Berning T, Waldendorf M, Glaser J, Gerlach U (1990) Immunoadsorbent plasma perfusion in patients with systemic lupus erythematosus. J Rheumatol 17(7):900–907, PubMed: 2213756PubMed

16.

Yamazaki Z, Idezuki Y, Inoue N, Yoshizawa H, Yamawaki N, Inagaki K et al (1989) Extracorporral imuunoadsorption with IM-PH or IM-TR column. Biomater Artif Cells Artif Organs 17(2):117–124, PubMed: 2673426CrossRefPubMed

17.

Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271–1277, PubMed: 7138600CrossRefPubMed

18.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725, PubMed: 9324032CrossRefPubMed

19.

Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677–2686, PubMed: 22553077CrossRefPubMedPubMedCentral

20.

Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD et al (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 64(6):797–808, PubMed: 22556106CrossRef

21.

Gladman DD, Ibañez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29(2):288–291, PubMed: 11838846PubMed

22.

Badsha H, Kong KO, Lian TY, Chan SP, Edwards CJ, Chng HH (2002) Low-dose pulse methylprednisolone for systemic lupus erythematosus flares is efficacious and has a decreased risk of infectious complications. Lupus 11(8):508–513, PubMed: 12220105CrossRefPubMed

23.

Kong KO, Badsha H, Lian TY, Edwards CJ, Chng HH (2004) Low-dose pulse methylprednisolone is an effective therapy for severe SLE flares. Lupus 13(3):212–213, PubMed: 15119552CrossRefPubMed

24.

Suzuki K (2000) The role of immunoadsorption using dextran-sulfate cellulose columns in the treatment of systemic lupus erythematosus. Ther Apher 4(3):239–243, PubMed: 10910027CrossRefPubMed

25.

Graninger M, Schmaldienst S, Derfler K, Graninger WB (2002) Immunoadsorption therapy (therasorb) in patients with severe lupus erythematosus. Acta Med Austriaca 29(1):26–29, PubMed: 11899750CrossRefPubMed

26.

Suzuki K, Hara M, Harigai M, Ishizuka T, Hirose T, Matsuki Y, Kawaguchi Y et al (1991) Continuous removal of anti-DNA antibody, using a new extracorporeal immunoadsorption system, in patients with systemic lupus erythematosus. Arthritis Rheum 34(12):1546–1552, PubMed: 1747139CrossRefPubMed

27.

Braun N, Jünger M, Klein R, Gutenberger S, Guagnin M, Risler T (2002) Dextran sulfate (Selesorb) plasma apheresis improves vascular changes in systemic lupus erythematosus. Ther Apher 6(6):471–477, PubMed: 12460414CrossRefPubMed

28.

Stefanutti C, Vivenzio A, Di Giacomo S, Mareri M, Ceccarelli F, Valesini G (2005) Cyclophosphamide and immunoadsorption apheresis treatment of lupus nephritis nonresponsive to drug therapy alone. BioDrugs 19(2):129–133, PubMed: 15807630CrossRefPubMed

29.

Palmer A, Cairns T, Dische F, Gluck G, Gjorstrup P, Parsons V et al (1991) Treatment of rapidly progressive glomerulonephritis by extracorporeal immunoadsorption, prednisolone and cyclophosphamide. Nephrol Dial Transplant 6(8):536–542, PubMed: 1956551CrossRefPubMed

30.

Schmaldienst S, Müllner M, Goldammer A, Spitzauer S, Banyai S, Hörl WH et al (2001) Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology (Oxford) 40(5):513–521CrossRef

31.

Takahashi S, Wada N, Harada K (2007) Immunoadsorbent apheresis eliminates pathogenic IgG in childhood lupus nephritis. Pediatr Int 49(6):817–821, PubMed: 18045278CrossRefPubMed

32.

Lhotta K, Würzner R, Rosenkranz AR, Beer R, Rudisch A, Neumair F et al (2004) Cerebral vasculitis in a patient with hereditary complete C4 deficiency and systemic lupus erythematosus. Lupus 13(2):139–141, PubMed: 14995009CrossRefPubMed

33.

Dittrich E, Schmaldienst S, Langer M, Jansen M, Hörl WH, Derfler K (2002) Immunoadsorption and plasma exchange in pregnancy. Kidney Blood Press Res 25(4):232–239, PubMed: 12424425CrossRefPubMed

34.

Stummvoll GH, Aringer M, Jansen M, Smolen JS, Derfler K, Graninger WB (2004) Immunoadsorption (IAS) as a rescue therapy in SLE: considerations on safety and efficacy. Wien Klin Wochenschr 116(21-22):716–724, PubMed: 15628641CrossRefPubMed

35.

Taniguchi Y, Yorioka N, Okushin S, Oda H, Usui K, Yamakido M (1995) Usefulness of immunoadsorption therapy for systemic lupus erythematosus associated with transverse myelitis. A case report. Int J Artif Organs 18(12):799–801, PubMed: 8964648PubMed

36.

Hershko AY, Scheiman-Elazari A, Aamar S, Naparstek Y (2013) Extracorporeal immunoadsorption of antibodies against the VRT-101 laminin epitope in systemic lupus erythematosus: a feasibility evaluation study. Immunol Res 56(2-3):376–381, PubMed: 23584986CrossRefPubMed

37.

Kronbichler A, Frank R, Kirschfink M, Szilágyi Á, Csuka D, Prohászka Z et al (2014) Efficacy of eculizumab in a patient with immunoadsorption-dependent catastrophic antiphospholipid syndrome: a case report. Medicine (Baltimore) 93(26), e143, PubMed:25474424CrossRef

38.

Ross S, Benz K, Sauerstein K, Amann K, Dötsch J, Dittrich K (2012) Unexpected recovery from longterm renal failure in severe diffuse proliferative lupus nephritis. BMC Nephrol 13:81, PubMed: 2286727

39.

Rech J, Hueber AJ, Kallert S, Requadt C, Kalden JR, Schulze-Koops H (2006) Immunoadsorption and CD20 antibody treatment in a patient with treatment resistant systemic lupus erythematosus and preterminal renal insufficiency. Ann Rheum Dis 65(4):552–553, PubMed: 16531554CrossRefPubMedPubMedCentral

40.

Stummvoll GH, Julius U, Derfler K, Aringer M (2009) Immunoadsorption for systemic lupus erythematosus. Atheroscler Suppl 10(5):110–113, PubMed: 20129387CrossRefPubMed

41.

Hauser AC, Hauser L, Pabinger-Fasching I, Quehenberger P, Derfler K, Hörl WH (2005) The course of anticardiolipin antibody levels under immunoadsorption therapy. Am J Kidney Dis 46(3):446–454, PubMed: 16129206CrossRefPubMed

42.

Maeshima E, Yamada Y, Kodama N, Mune M, Yukawa S (1999) Successful pregnancy and delivery in a case of systemic lupus erythematosus treated with immunoadsorption therapy and cyclosporin A. Scand J Rheumatol 28(1):54–57, PubMed: 10092166CrossRefPubMed

43.

Schmaldienst S, Jansen M, Hollenstein U, Graninger W, Regele H, Hörl WH et al (2002) Treatment of systemic lupus erythematosus by immunoadsorption in a patient suffering from tuberculosis. Am J Kidney Dis 39:415–418, PubMed: 11840385CrossRefPubMed

Title: Rapid reduction of antibodies and improvement of disease activity by immunoadsorption in Chinese patients with severe systemic lupus erythematosus
Authors: Jinxian Huang
Guoxiang Song
Zhihua Yin
Weizhen He
Lijun Zhang
Weihong Kong
Zhizhong Ye
Publication date: 01-09-2016
Publisher: Springer London
Published in: Clinical Rheumatology / Issue 9/2016
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-016-3354-2

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2016

IL-37 inhibits the production of pro-inflammatory cytokines in MSU crystal-induced inflammatory response

Factors influencing adherence among older people with osteoarthritis

A complex role of anthrax toxin receptor 2 polymorphisms and capillary morphogenesis protein 2 in ankylosing spondylitis pathogenesis

Letter to the Editor: “Comparison of efficacy of kinesiological taping and subacromial injection therapy in subacromial impingement syndrome”

Politics, culture, and the legitimacy of disease: the case of Buerger’s disease

Identification of citrullinated peptides in the synovial fluid of patients with rheumatoid arthritis using LC-MALDI-TOF/TOF

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials